Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Outstanding (Weighted Average) (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Shares Outstanding (Weighted Average) data on record, last reported at $41.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 11.11% year-over-year to $41.8 million; the TTM value through Dec 2025 reached $41.8 million, up 11.11%, while the annual FY2025 figure was $41.8 million, 11.11% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $41.8 million in Q4 2025 per TARS's latest filing, down from $42.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $42.6 million in Q3 2025 and bottomed at $20.3 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $30.1 million, with a median of $28.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 675.42% in 2021, then increased 1.84% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $20.6 million in 2021, then increased by 19.78% to $24.6 million in 2022, then grew by 19.35% to $29.4 million in 2023, then rose by 27.98% to $37.6 million in 2024, then rose by 11.11% to $41.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $41.8 million in Q4 2025, $42.6 million in Q3 2025, and $42.4 million in Q2 2025.